Aims: To compare the effects of ezetimibe plus orlistat or rimonabant on anthropometric and lipid parameters in nondiabetic statin-intolerant overweight/obese patients with dyslipidemia.
Methods and results: Thirty participants received a hypocaloric diet and were randomized to open-label combination of ezetimibe (10 mg/day) with orlistat (120 mg, 3 times a day with meals; ezetimibe/orlistat [EO], n = 15) or rimonabant (20 mg/day; ezetimibe/ rimonabant [ER], n = 15). Anthropometric and metabolic variables were assessed at baseline and 3 months posttreatment. Similar reductions in body weight, body mass index, and waist circumference were recorded in both groups (—8.3%, —8.6%, and —5.2% in the EO group and —7.3%, —7.2%, and —7.0% in the ER group, P < .01 vs baseline for all). Low-density lipoprotein cholesterol (LDL-C) levels decreased in both treatment groups, but this reduction tended to be more pronounced in the EO group (28.4% vs 15.3%, respectively; P < .01 vs baseline for both). Triglycerides tended to decrease more in the ER compared with the EO group (—20.4% vs —14.1%, P < .01 vs baseline for both). High-density lipoprotein cholesterol (HDL-C) levels tended to decrease in EO group, but remained unaltered with ER treatment. Apolipoprotein B levels were equally reduced in both treatment groups. Conclusion: For similar body weight reduction, the combination of ezetimibe with orlistat may be more efficient in LDL-C lowering, whereas the combination of ezetimibe with rimonabant may be more potent in terms of improving HDL-C and triglycerides.
Klein S., Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2004;110(18):2952-2967.
2.
Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002 . JAMA. 2005;294(14):1773-1781.
3.
Liberopoulos EN, Mikhailidis DP, Elisaf MSDiagnosis and management of the metabolic syndrome in obesity. Obes Rev. 2005;6(4):283-296.
4.
Wadden TA, Butryn MLBehavioral treatment of obesity. Endocrinol Metab Clin North Am. 2003;32(4): 981-1003.
5.
Kiortsis DN, Filippatos TD, Elisaf MSThe effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab. 2005;31(1):15-22.
6.
Nakou ES, Filippatos TD, Georgoula M., et al. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin. 2008;24(7):1919-1929.
7.
Pagotto U., Marsicano G., Cota D., Lutz B., Pasquali R.The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. 2006;27(1):73-100.
8.
Van Gaal L., Pi-Sunyer X., Despres JP, McCarthy C., Scheen A.Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care. 2008 ;31(Suppl 2):S229-240.
9.
Press Release-The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia. http://www.emea.europa.eu/ . Accessed June 20, 2008.
10.
Baigent C., Keech A., Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493): 1267-1278.
Mikhailidis DP, Wierzbicki AS, Daskalopoulou SS, et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr Med Res Opin. 2005;21(6):959-969.
13.
Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
14.
Florentin M. , Liberopoulos EN, Elisaf MSEzetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract. 2008;62(1):88-96.
15.
Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement . Circulation. 2005;112(17): 2735-2752.
Davidson MH , Hauptman J., DiGirolamo M., et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281(3):235-242.
18.
Sjostrom L. , Rissanen A., Andersen T., et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients . European Multicentre Orlistat Study Group. Lancet. 1998; 352(9123):167-172.
19.
Bakris G., Calhoun D., Egan B., Hellmann C., Dolker M., Kingma I.Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens. 2002;20(11):2257-2267.
20.
Swinburn BA , Carey D., Hills AP, et al. Effect of orlistat on cardiovascular disease risk in obese adults. Diabetes Obes Metab. 2005;7(3):254-262.
21.
Guy-Grand B. , Drouin P., Eschwege E., Gin H., Joubert JM, Valensi P.Effects of orlistat on obesity-related diseases-a six-month randomized trial. Diabetes Obes Metab. 2004;6(5):375-383.
22.
Muls E., Kolanowski J., Scheen A., Van Gaal L.The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord. 2001 ;25(11):1713-1721.
23.
Noakes M., Keogh JB, Foster PR, Clifton PMEffect of an energy-restricted, high-protein, low-fat diet relative to a conventional high-carbohydrate, low-fat diet on weight loss, body composition, nutritional status, and markers of cardiovascular health in obese women. Am J Clin Nutr. 2005;81(6):1298-1306.
24.
Sartorio A., Lafortuna CL, Vangeli V., Tavani A., Bosetti C., La Vecchia C.Short-term changes of cardiovascular risk factors after a non-pharmacological body weight reduction program. Eur J Clin Nutr. 2001; 55(10):865-869.
25.
Florentin M., Liberopoulos EN, Filippatos TD, et al. Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/ obese patients: a pilot study . Expert Opin Pharmacother. 2008;9(16):2741-2750.
26.
Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M., Mikhailidis DP, Elisaf MSEffect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin. 2005;21(12):1997-2006.
27.
Kalogirou M. , Tsimihodimos V., Gazi I., et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia . Curr Med Res Opin. 2007;23(5): 1169-1176.
28.
Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DPEffect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin . Curr Med Res Opin. 2007;23(9):2183-2192.
29.
Kastelein JJ , van der Steeg WA, Holme I., et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008; 117(23):3002-3009.
30.
Gazi IF, Tsimihodimos V., Tselepis AD, Elisaf M., Mikhailidis DPClinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther. 2007;7(1):53-72.
31.
Florentin M. , Liberopoulos EN, Wierzbicki AS, Mikhailidis DPMultiple actions of high-density lipoprotein . Curr Opin Cardiol. 2008;23(4):370-378.
32.
McQueen MJ, Hawken S., Wang X., et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372(9634):224-233.
33.
Daskalopoulou SS, Mikhailidis DP, Elisaf M.Prevention and treatment of the metabolic syndrome. Angiology. 2004;55(6):589-612.
34.
Koenig W., Lowel H., Baumert J., Meisinger C.C-reactive protein modulates risk prediction based on the Framing-ham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. 2004;109(11):1349-1353.
35.
Ridker PM, Danielson E., Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21): 2195-2207.
36.
Nissen SE, Nicholls SJ, Wolski K., et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA. 2008;299(13):1547-1560.
